IL-10 Modulation of Kupffer Cells for Cholesterol Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypercholesterolemia primarily focus on inhibiting dietary cholesterol uptake and hepatocellular cholesterol synthesis, but these methods have limitations and adverse effects, and there is a need for alternative mechanisms to effectively manage high cholesterol levels and associated cardiovascular risks.
Innovation Solution
The use of IL-10, particularly pegylated IL-10, and associated agents to modulate Kupffer cell activity and homeostasis, enhancing their capacity to remove lipoproteins from the serum, thereby reducing cholesterol levels and addressing hypercholesterolemia and related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional lipid-lowering agents are used to reduce cholesterol production or absorption, then cholesterol levels are effectively lowered, but adverse effects and limitations occur
Solution Approach 1:
The patent introduces IL-10 as an intermediary substance that mediates cholesterol reduction by acting on Kupffer cells. Instead of directly inhibiting cholesterol production or absorption, IL-10 serves as a mediator that activates Kupffer cells to enhance their lipid clearance function, thereby lowering cholesterol levels through a different mechanistic pathway that avoids the adverse effects of conventional agents
Solution Approach 2:
The patent changes the physiological parameter of Kupffer cell activity and homeostasis to achieve cholesterol reduction. By modulating these parameters through IL-10 administration, the system enhances the natural clearance capacity of the immune system rather than directly suppressing cholesterol synthesis or absorption, leading to effective cholesterol lowering with fewer adverse effects
2Adaptability or versatility
If conventional agents acting through cholesterol production or absorption inhibition are used, then most patient populations are treated effectively, but alternative mechanisms are needed to provide therapeutic options
Solution Approach 1:
The patent applies universality by demonstrating that IL-10 can lower cholesterol levels through a mechanism that is broadly applicable across different patient populations. The approach targets Kupffer cells, which are present in all individuals, providing a universal therapeutic mechanism that may work regardless of the specific cause of hypercholesterolemia, thereby expanding therapeutic options without significantly increasing complexity
Data Source
AI summary
Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating Kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an IL-10 agent are also provided.